InsiderSignal.AI

InsiderSignal.ai

RLMD - Relmada Therapeutics, Inc.

Insider Purchase by Traversa Sergio (CEO)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Traversa Sergio, serving as CEO at Relmada Therapeutics, Inc. (RLMD), purchased 272,500 shares at $2.20 per share, for a total transaction value of $599,500.00. Following this transaction, Traversa Sergio now holds 1,272,500 shares of RLMD.

This purchase represents a 27.00% increase in Traversa Sergio's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, November 5, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, November 6, 2025, 1 day after the trade was made.

Relmada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Traversa Sergio

CEO

Sergio Traversa (age 64) is the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage biotechnology company, a position he has held since April 2012.[[1]](https://fintool.com/app/research/companies/RLMD/people/sergio-traversa)[[2]](https://www.relmada.com/company) Under his leadership, Relmada executed a strategic pivot in 2024–2025, pausing programs like REL-1017 and REL-P11 following Phase 3 data, and in-licensing NDV-01 for NMIBC from Trigone and acquiring sepranolone from Asarina to focus on nearer-term value drivers, with key milestones including NDV-01 Phase 2 data at AUA 2025.[[1]](https://fintool.com/app/research/companies/RLMD/people/sergio-traversa) Traversa brings over 25 years of experience in healthcare across pharmaceuticals, investing, and advisory roles in the US and Europe.[[2]](https://www.relmada.com/company) His career highlights include co-founding and serving as CEO of Medeor Inc. (2010–2012), a Cornell University spinoff; founding partner at Ardana Capital (2008–2010); Area Manager for Southern Europe at Therakos (Johnson & Johnson); and Marketing Manager in Eli Lilly's Hospital Business Unit and CNS team, contributing to Prozac launch and early Zyprexa/Cymbalta development.[[1]](https://fintool.com/app/research/companies/RLMD/people/sergio-traversa)[[2]](https://www.relmada.com/company) He holds a Laurea in Pharmacy from the University of Turin and an MBA in Finance/International Business from NYU Stern.[[1]](https://fintool.com/app/research/companies/RLMD/people/sergio-traversa)[[2]](https://www.relmada.com/company)

View full insider profile →

Trade Price

$2.20

Quantity

272,500

Total Value

$599,500.00

Shares Owned

1,272,500

Trade Date

Wednesday, November 5, 2025

109 days ago

SEC Filing Date

Thursday, November 6, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Relmada Therapeutics, Inc.

Company Overview

No company information available
View news mentioning RLMD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/1087923

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime